Feb 6 (Reuters) - Allergan Plc:
* ALLERGAN ANNOUNCES POSITIVE TOP LINE PHASE 3 RESULTS FOR UBROGEPANT - AN ORAL CGRP RECEPTOR ANTAGONIST FOR THE ACUTE TREATMENT OF MIGRAINE
* STUDY MEETS CO-PRIMARY ENDPOINTS IN FIRST OF TWO PHASE 3 STUDIES
* STUDY MEETS CO-PRIMARY ENDPOINTS IN FIRST OF TWO PHASE 3 STUDIES
* RESULTS OF SECOND PHASE 3 TRIAL, ACHIEVE II (UBR-MD-02), ARE EXPECTED IN 1ST HALF OF 2018
* ALLERGAN - ANTICIPATES FILING NDA TO FDA FOR ACUTE MIGRAINE TREATMENT DRUG IN 2019 Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.